10x Genomics Inc. stocks have been trading up by 7.52 percent after upbeat earnings signaled strengthening demand and profitability
Click Here for a Millionaire's POV on Trading TXG
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways For TXG Traders
- Patent win against Qiagen’s Parse Biosciences confirms three Scale Biosciences single-cell patents, delivers over $4.8M in damages, and sets up TXG to pursue enhanced damages and a possible U.S. injunction.
- A new AI pathology partnership with Korea-based Lunit ties Lunit SCOPE IO to Xenium and Atera, deepening TXG’s role in oncology biomarker discovery and immunotherapy response prediction workflows.
- RBC launched coverage at Sector Perform with a $70 target, flagging TXG’s >60% spatial profiling share but warning that core single-cell revenue may stay flat over the next five years.
- UBS went Neutral at $68 while Deutsche Bank lifted its TXG target to $70 from $40 but stayed Hold, leaving the stock with an average Overweight rating and consensus target near $52.
- Recent Form 4 filings show CFO Adam Taich and director John R. Stuelpnagel selling a combined ~$4.2M in TXG shares, though both insiders still hold substantial Class A positions.
Live Update At 12:32:40 EDT: On Thursday, September 24, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 7.52%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TXG has been on a sharp uptrend. From late August closes near $62, 10x Genomics has ripped to about $81.5, a gain of roughly 30% in under a month. That’s momentum traders pay attention to. The recent daily candles show strong pushes off dips, with TXG bouncing from lows near $64 on 2026/09/14 to the low $80s by 2026/09/24.
Intraday, TXG’s 5‑minute chart shows steady buying pressure. After opening around $75.5, the stock pushed through $80, tapped an intraday high above $82, and held most of those gains into midday. That tells traders dip buyers are in control for now, with higher lows building a solid short-term trend.
Under the hood, TXG remains a high-growth, not-yet-profitable name. Quarterly revenue of about $151.0M sits on a rich 70% gross margin, but operating losses still run near $22.9M, and net margin is negative. Cash is a plus: over $502.5M in cash and equivalents, low debt, and a current ratio above 5 give TXG room to keep funding R&D and platforms like Xenium and Atera.
More Breaking News
- Stellantis Stock Slides As Downgrades, Shutdowns Rattle Traders
- Wingstop Stock Draws Bullish Targets As NFL Promotions Kick Off
- YMT Stock Slides As Volatility And Weak Fundamentals Collide
- LITE Stock Jumps As Citi Hikes Target On AI Optics Hype
Valuation is stretched. A price-to-sales ratio around 17 and price-to-book near 12.7 place TXG firmly in “story stock” territory. Traders are paying up for future growth, especially in spatial biology, and that makes TXG very sensitive to headlines and guidance shifts.
Why Traders Are Watching TXG Momentum
TXG is at the center of several big storylines right now, and traders love a stock where the narrative and the chart line up. On the business side, 10x Genomics just notched a key legal win. A Delaware federal jury confirmed that three Scale Biosciences single‑cell patents were valid and infringed by Qiagen’s Parse Biosciences unit. The award — over $4.8M tied to a 14% royalty on Evercode Whole Transcriptome sales from 2021 to mid‑2026 — is not life‑changing cash for TXG, but it reinforces the company’s moat around single‑cell analysis.
TXG plans to chase enhanced damages, attorneys’ fees, and a possible U.S. injunction against the infringing products. For traders, that points to ongoing leverage in this IP battle. Yet even with this win, TXG traded down around 5% on the headline in a weak healthcare tape. That disconnect shows how sector flows can overpower stock‑specific good news, an important reminder when trading biotech tools names.
At the same time, TXG is pressing deeper into AI‑driven oncology. The new tie‑up with Korea‑based Lunit brings Lunit SCOPE IO — an AI pathology engine — into 10x Genomics’ biomarker discovery workflow. By combining H&E image analysis with spatial molecular data from Xenium and Atera, TXG is positioning itself as a critical piece of antibody‑drug conjugate development and immunotherapy response prediction. That kind of integration story is exactly what helps support the high multiple traders are paying.
Wall Street coverage is catching up with the price action. RBC’s Sector Perform at $70 and UBS’s Neutral at $68 show respect for TXG’s technology but also restraint. RBC points to strong double‑digit growth and more than 60% share in spatial profiling, while warning that core single‑cell revenue may stay flat over five years. Deutsche Bank moving its target from $40 to $70, yet still sitting at Hold, sends a similar message: TXG is executing, but expectations already run hot.
Conclusion
TXG sits in that tricky zone where the story is strong, the chart is hot, and the bar is high. The company delivers 70% gross margins on more than $642.8M in annual revenue, dominates spatial profiling, and just showed it can defend its patents in court. Cash flow has turned positive in the latest quarter, with about $16.9M from operations and roughly $15.4M in free cash flow, even while TXG continues to pour money into R&D and platform expansion.
At the same time, the numbers remind traders why this is still a battleground. Profitability metrics are negative, returns on capital and equity are in the red, and valuation multiples for TXG assume that spatial biology growth will more than offset flat single‑cell revenue. Add in recent insider sales — roughly $3.0M from CFO Adam Taich and $1.24M from director John R. Stuelpnagel — and you get a backdrop where every earnings print and product update matters for TXG.
For short‑term traders, the current trend in TXG is clear: higher highs, strong intraday support, and news‑driven spikes backed by a real business story. But this is still a volatile, premium‑priced name in a choppy biotech tools tape. As Tim Sykes likes to say, “Trade the ticker, not the story — patterns pay, hype fades.” As Tim Bohen, lead trainer with StocksToTrade says, “A consistent trading routine beats sporadic action every time. Show up daily, and you’ll start to see the patterns others miss.” TXG gives plenty of story, but disciplined traders will focus on the chart, manage risk tightly, and treat every setup as a trade, not a promise. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.